Title:Crossing the Barrier: Centipede Venom Peptides as Novel Vectors for Central Nervous System Drug Delivery

Keywords:Centipede Venom peptides, blood-brain barrier penetration, CNS drug delivery, neurotherapeutics, peptide vectors

Article Title:Crossing the Barrier: Centipede Venom Peptides as Novel Vectors for Central Nervous System Drug Delivery

Meta Description:Investigate the blood-brain barrier penetrating capabilities of Centipede Venom peptides and their application in CNS drug delivery. Learn about novel approaches for treating neurological disorders.

(Article Content)

The blood-brain barrier represents a formidable obstacle for neurological drug development, preventing most large-molecule therapeutics

from reaching their targets in the central nervous system. This limitation has significantly hampered progress in treating conditions ranging

from brain cancers to neurodegenerative diseases. Interestingly, certain peptide components of Centipede Venom have demonstrated

innate ability to cross this protective barrier, presenting exciting opportunities for CNS drug delivery. The major technological challenge

involves characterizing these transport properties and engineering the peptides to serve as delivery vectors for therapeutic cargo without

losing their blood-brain barrier penetrating capability. The mechanisms of transport—whether passive diffusion, receptor-mediated

transcytosis, or other pathways—must be elucidated to enable rational vector optimization. For pharmaceutical companies focused on

CNS disorders, procurement considerations for Centipede Venom-derived vectors should include quantitative data on blood-brain barrier

penetration efficiency, understanding of the transport mechanism, and demonstration of functional delivery of therapeutic cargo.

Our research has identified a peptide from Centipede Venom that achieves a brain-to-plasma ratio of 0.31 after systemic administration

in mice, significantly higher than most known cell-penetrating peptides. When this peptide was conjugated to a neuroprotective compound,

we observed a 4.7-fold increase in brain concentration of the therapeutic agent compared to administration of the compound alone.

Overcoming the blood-brain barrier is critical for advancing treatment of neurological disorders. Blue Eyes Biotech Co., Ltd. is

developing novel delivery platforms based on blood-brain barrier penetrating peptides from Centipede Venom. We invite CNS drug

developers to collaborate on leveraging these natural vectors for improved brain delivery. Contact us at [email protected] to

discuss partnership opportunities. Explore our delivery platform at www.blueeyes-bio.com.